# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K210341   
B Applicant SPD Swiss Precision Diagnostics GmbH   
C Proprietary and Established Names One Step Pregnancy Test   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>LCX</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.1155 -Human ChorionicGonadotropin (Hcg)Test System</td><td rowspan=1 colspan=1>CH - ClinicalChemistry</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: New device   
B Measurand: Human chorionic gonadotropin (hCG)   
C Type of Test: Qualitative chromatographic immunoassay

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

One Step Pregnancy Test is an over-the-counter lateral flow immunoassay for the qualitative detection of human chorionic gonadotropin (hCG) in urine. The visual test is intended for home use as an aid in early detection of pregnancy. The test is indicated for use from 4 days before the expected period (5 days before the missed period).

C Special Conditions for Use Statement(s): OTC - Over The Counter

D Special Instrument Requirements: None

IV Device/System Characteristics:

# A Device Description:

The One Step Pregnancy Test is an immunochromatographic sandwich assay containing a lateral flow test strip housed in a cassette. Each test contains one cassette packaged in a pouch and one pipette dropper.

# B Principle of Operation:

The test strip contains monoclonal anti-hCG antibodies and goat anti-mouse polyclonal antibody. The test result is shown in the result window and read visually between 3 - 10 minutes of urine application. If hCG is present in the urine sample, it is bound by a conjugated monoclonal anti α- hCG antibody forming an anti hCG-antibody-gold complex. The sample is drawn through the nitrocellulose membrane by capillary action. At the test (T) line, any hCG present is bound by immobilized anti- $\beta \mathop { \mathrm { h C G } }$ antibody forming a sandwich, immobilizing gold particles, and giving rise to a colored line. If no hCG is present in the sample, there is no binding at the test line and subsequently, no colored line. The appearance of two colored lines in the result window, the test (T) line and control (C) line, indicates a positive result. The appearance of one colored line in the result window, the control (C) line, indicates a negative result. If there is no control (C) line, the test has not run correctly and is an invalid result.

# V Substantial Equivalence Information:

A Predicate Device Name(s): QUIK-CHECK Home Pregnancy Test   
B Predicate 510(k) Number(s): K012215

# C Comparison with Predicate(s):

<table><tr><td rowspan=1 colspan=1>Device &amp; PredicateDevice(s):</td><td rowspan=1 colspan=1>K210341</td><td rowspan=1 colspan=1>K012215</td></tr><tr><td rowspan=1 colspan=1>Device Trade Name</td><td rowspan=1 colspan=1>One Step PregnancyTest</td><td rowspan=1 colspan=1>QUIK-CHECK HomePregnancy Test</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristic Similarities</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Intended Use/IndicationsFor Use</td><td rowspan=1 colspan=1>For the qualitativedetection of hCG inurine as an aid in theearly detection ofpregnancy</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Type of use</td><td rowspan=1 colspan=1>Over-the-counter use</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Chromatographicimmunoassay</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Specimen type</td><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>25 mIU/mL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristic Differences</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Early Detection Claim</td><td rowspan=1 colspan=1>Pregnancy can bedetected as early as 4days before the date ofthe expected period (5days before missedperiod)</td><td rowspan=1 colspan=1>Not tested for thisdevice</td></tr></table>

# VI Standards/Guidance Documents Referenced:

None referenced.

VII Performance Characteristics (if/when applicable):

A. Analytical Performance:

1. Precision/Reproducibility:

A pooled negative urine sample was spiked with hCG to provide eight urine samples with hCG concentrations of $< 0 . 5$ , 12.5, 15, 18, 25, 50, 100 and $2 0 0 \mathrm { m I U / m L }$ . Each sample was tested in replicates of five by three operators using four test lots over 3 non-consecutive days. A total of 180 replicates per hCG concentration were tested across 4 lots. The device cutoff is $2 5 \mathrm { m I U / m L }$ hCG.

Overall precision results   

<table><tr><td rowspan=1 colspan=1>hCG Concentration(mIU/mL)</td><td rowspan=1 colspan=1>Total(n)</td><td rowspan=1 colspan=1>Positive(n)</td><td rowspan=1 colspan=1>Negative(n)</td><td rowspan=1 colspan=1>% PositiveResults</td></tr><tr><td rowspan=1 colspan=1>&lt;0.5</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>0.0</td></tr><tr><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>180</td><td rowspan=2 colspan=1>3076</td><td rowspan=3 colspan=1>15010435</td><td rowspan=3 colspan=1>16.742.280.6</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>180</td></tr><tr><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>145</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>180</td><td rowspan=2 colspan=1>180180</td><td rowspan=2 colspan=1>00</td><td rowspan=2 colspan=1>100.0100.0</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>180</td></tr><tr><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>1440</td><td rowspan=1 colspan=1>971</td><td rowspan=1 colspan=1>469</td><td rowspan=1 colspan=1>N/A</td></tr></table>

Precision results for each device lot   

<table><tr><td rowspan=2 colspan=1>hCGconcentration(mIU/mL)</td><td rowspan=1 colspan=2>Lot 1</td><td rowspan=1 colspan=2>Lot 2</td><td rowspan=1 colspan=2>Lot 3</td><td rowspan=1 colspan=2>Lot 4</td></tr><tr><td rowspan=1 colspan=1>n#Positive#Negative</td><td rowspan=1 colspan=1>%Positive</td><td rowspan=1 colspan=1>#Positive#Negative</td><td rowspan=1 colspan=1>%Positive</td><td rowspan=1 colspan=1>#Positive#Negative</td><td rowspan=1 colspan=1>%Positive</td><td rowspan=1 colspan=1>#Positive#Negative</td><td rowspan=1 colspan=1>% Positive</td></tr><tr><td rowspan=1 colspan=1>&lt;0.5</td><td rowspan=1 colspan=1>0/45</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0/45</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0/45</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0/45</td><td rowspan=1 colspan=1>0.0</td></tr><tr><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>7/38</td><td rowspan=1 colspan=1>15.6</td><td rowspan=1 colspan=1>8/37</td><td rowspan=1 colspan=1>17.8</td><td rowspan=1 colspan=1>6/39</td><td rowspan=1 colspan=1>13.3</td><td rowspan=1 colspan=1>9/36</td><td rowspan=1 colspan=1>20.0</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>16/29</td><td rowspan=1 colspan=1>35.6</td><td rowspan=1 colspan=1>22/23</td><td rowspan=1 colspan=1>48.9</td><td rowspan=1 colspan=1>19/26</td><td rowspan=1 colspan=1>42.2</td><td rowspan=1 colspan=1>19/26</td><td rowspan=1 colspan=1>42.2</td></tr><tr><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>35/10</td><td rowspan=1 colspan=1>77.8</td><td rowspan=1 colspan=1>38/7</td><td rowspan=1 colspan=1>84.4</td><td rowspan=1 colspan=1>37/8</td><td rowspan=1 colspan=1>82.2</td><td rowspan=1 colspan=1>35/10</td><td rowspan=1 colspan=1>77.8</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>45/0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>45/0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>45/0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>45/0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>45/0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>45/0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>45/0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>45/0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>45/0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>45/0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>45/0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>45/0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>45/0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>45/0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>45/0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>45/0</td><td rowspan=1 colspan=1>100</td></tr></table>

# 2. Linearity:

Not applicable. This is a qualitative device.

3. Analytical Specificity/Interference:

# Cross-reactivity:

The One Step Pregnancy Test device was tested for potential cross-reactivity from luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH). Urine specimens from non-pregnant females were pooled and used to prepare samples with hCG levels $< 0 . 5 \mathrm { m I U / m L }$ and $2 5 \mathrm { m I U / m L }$ that were then spiked with 500 mIU/mL LH, 1000 mIU/mL FSH, and $1 \ \mathrm { m I U / m L }$ TSH.

The results demonstrated no cross-reactivity up to $5 0 0 \ \mathrm { m I U / m L }$ LH, 1000 mIU/mL FSH, and $1 \ \mathrm { m I U / m L }$ TSH in either negative or positive urine samples.

# Interference:

The One Step Pregnancy Test device was tested with potentially interfering substances. Urine specimens from non-pregnant females were pooled and used to prepare samples with hCG levels $< 0 . 5 \mathrm { m I U / m L }$ and $2 5 \mathrm { m I U / m L }$ that were then spiked with interfering substances. Each condition was tested with five devices from each of three lots for each of the two hCG concentrations. No interference effect was observed at the tested concentrations shown in table below:

<table><tr><td rowspan=1 colspan=1>Interfering Substance</td><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>Interfering Substance</td><td rowspan=1 colspan=1>Concentration</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic acid</td><td rowspan=1 colspan=1>1.0mg/mL</td><td rowspan=1 colspan=1>Gentisic acid</td><td rowspan=1 colspan=1>200μg/mL</td></tr><tr><td rowspan=1 colspan=1>Acetone</td><td rowspan=1 colspan=1>1.0mg/mL (0.125% v/v)</td><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>100μg/mL</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>5mg/mL</td><td rowspan=1 colspan=1>Hydrochloric acid</td><td rowspan=1 colspan=1>1.25mM</td></tr><tr><td rowspan=1 colspan=1>Ampicillin</td><td rowspan=1 colspan=1>200μg/mL</td><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>100μg/mL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid</td><td rowspan=1 colspan=1>150μg/mL</td><td rowspan=1 colspan=1>Leukocytes</td><td rowspan=1 colspan=1>1x106 cells/mL</td></tr><tr><td rowspan=1 colspan=1>Atropine</td><td rowspan=1 colspan=1>200μg/mL</td><td rowspan=1 colspan=1>Oxytetracycline</td><td rowspan=1 colspan=1>300μg/mL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>200μg/mL</td><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>600μg/mL</td></tr><tr><td rowspan=1 colspan=1>Blood</td><td rowspan=1 colspan=1>0.3% v/v</td><td rowspan=1 colspan=1>Pregnanediol-3-glucuronide</td><td rowspan=1 colspan=1>40μg/mL</td></tr><tr><td rowspan=1 colspan=1>Caffeine</td><td rowspan=1 colspan=1>1.2mg/mL</td><td rowspan=1 colspan=1>Phenylpropanolamine</td><td rowspan=1 colspan=1>200μg/mL</td></tr><tr><td rowspan=1 colspan=1>Cannabinol</td><td rowspan=1 colspan=1>100μg/mL</td><td rowspan=1 colspan=1>Semen</td><td rowspan=1 colspan=1>5% v/v</td></tr><tr><td rowspan=1 colspan=1>Clomiphene citrate</td><td rowspan=1 colspan=1>24μg/mL</td><td rowspan=1 colspan=1>Sodium hydroxide</td><td rowspan=1 colspan=1>1.25mM</td></tr><tr><td rowspan=1 colspan=1>Cotinine</td><td rowspan=1 colspan=1>40μg/mL</td><td rowspan=1 colspan=1>Tetracycline</td><td rowspan=1 colspan=1>300μg/mL</td></tr><tr><td rowspan=1 colspan=1>Ethanol</td><td rowspan=1 colspan=1>5% v/v</td><td rowspan=1 colspan=1>Urea</td><td rowspan=1 colspan=1>30mg/mL</td></tr><tr><td rowspan=1 colspan=1>Estrone-3-glucoronide</td><td rowspan=1 colspan=1>620ng/mL</td><td rowspan=1 colspan=1>Uric acid</td><td rowspan=1 colspan=1>750μg/mL</td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>20mg/mL</td><td rowspan=1 colspan=1>Urobilinogen</td><td rowspan=1 colspan=1>100μg/mL</td></tr></table>

# Effect of hCG β-core fragment:

To evaluate potential interference from $\mathsf { h C G } $ core fragment $( \mathrm { h C G } \mathrm { \beta c f } )$ , several combinations and concentrations of hCG and hCGβcf were tested using multiple devices from 3 lots. No hCGβcf interference was observed for the following test conditions:

$\bigcirc$ Positive urine samples (pooled from pregnant females that were at weeks 6-7 from last menstrual period) spiked up to $1 \mu \mathrm { M } \mathrm { h C G } \mu \mathrm { d } \epsilon \mathrm { f } .$ .   
o Negative pooled urine $( < 0 . 5 \mathrm { m I U / m L \ : h C G } )$ spiked with hCG to a concentration representative of a sample from a 6-7 weeks pregnant female $( 2 5 , 3 6 2 \mathrm { m I U / m L } )$ , then spiked with $1 \mu \mathrm { M } \mathrm { h C G } \mu \mathrm { c f . }$   
o Positive urine samples (pooled from pregnant females that were at weeks 9-12 from last menstrual period) spiked up to $1 \mu \mathrm { M }$ hCGβcf.   
$\bigcirc$ Negative pooled urine spiked with hCG to a concentration representative of a sample from a 9-12 weeks pregnant female $4 6 { , } 9 2 0 \mathrm { m U / m L }$ ), then spiked with $1 \mu \mathrm { M }$ hCGβcf.   
o Negative pooled urine spiked to $2 5 \mathrm { m I U / m L }$ hCG, then spiked with hCGβcf to a concentration 5x the molar concentration of hCG (i.e., 375 pM hCGβcf).

# Effect of urine pH:

To evaluate potential interference from changes in pH, urine samples containing $0 \mathrm { m U / m L }$ and $2 5 \mathrm { m I U / m L }$ hCG were tested at $\mathsf { p H }$ values of 4.0 to 9.0. Each hCG concentration was tested with 15 devices, five from each of three lots per $\mathsf { p H }$ condition. The results demonstrated that samples within the $\mathsf { p H }$ range of 4.0 to 9.0 do not interfere with either positive or negative results from the device.

# Effect of urine specific gravity:

To evaluate potential interference from changes in specific gravity, urine samples containing $< 0 . 5 \mathrm { m I U / m L }$ and $2 5 \mathrm { m I U / m L }$ hCG were adjusted to a specific gravity values from 1.000 to 1.035. Each hCG concentration was tested with 15 devices, five from each of three lots per

specific gravity condition. The results demonstrated that samples within the specific gravity range of 1.000 to 1.035 do not interfere with either positive or negative results from the device.

# Hook effect study:

Negative pooled urine was spiked with hCG to concentrations of $< 0 . 5$ , 25, 250,000, 500,000, or $1 , 0 0 0 , 0 0 0 \mathrm { m I U / m L }$ and tested in five replicates per each of three lots. No hook effect was observed at concentrations of up to $1 , 0 0 0 , 0 0 0 \mathrm { m I U / m L }$ hCG.

4. Assay Reportable Range: Not applicable. This is a qualitative test.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

Traceability:   
The One Step Pregnancy Test is traceable to the WHO 4th International Standard for human Chorionic Gonadotropin (hCG) (NIBSC code 75/589).

6. Detection Limit: The device cut-off is $2 5 \mathrm { m I U / m L }$ . See Precision/Reproducibility section (Section VII.A.1.) above.

7. Assay Cut-Off:

The device cut-off is $2 5 \mathrm { m I U / m L }$ . See Precision/Reproducibility (Section VII.A.1.) section above.

# B. Comparison Studies:

1. Method Comparison with Predicate Device:

A total of 150 urine samples from pregnant women and 150 urine samples from non-pregnant women were tested by trained technicians using devices across three lots of the One Step Pregnancy Test and the predicate device. The results are summarized below.

<table><tr><td rowspan=2 colspan=1>One Step Pregnancy Test</td><td rowspan=1 colspan=3>Predicate device</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>150</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>150</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>300</td></tr></table>

The data show that the agreement of the One Step Pregnancy Test with the predicate device was $100 \%$ .

2. Matrix Comparison: Not Applicable. The device is intended for urine samples only.

# C. Clinical Studies:

1. Clinical Sensitivity:

Not Applicable

2. Clinical Specificity: Not Applicable

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):

a. Detection of hCG in Early Pregnancy Clinical Samples:

A total of 1197 One Step Pregnancy Test devices were tested across 3 lots with urine samples collected from days -9 to 0 relative to the day of the expected menstrual period from 272 different women aged 18 to 55 years who planned to become pregnant. The early pregnancy detection results are summarized in table below:

<table><tr><td rowspan=1 colspan=1>Days Relative to expectedmenstrual period</td><td rowspan=1 colspan=1>Total (n)</td><td rowspan=1 colspan=1>Positive (n)</td><td rowspan=1 colspan=1>% Positive</td></tr><tr><td rowspan=1 colspan=1>-9</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>-8</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>-7</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>13.3</td></tr><tr><td rowspan=1 colspan=1>-6</td><td rowspan=1 colspan=1>132</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>43.2</td></tr><tr><td rowspan=1 colspan=1>-5</td><td rowspan=1 colspan=1>132</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>64.4</td></tr><tr><td rowspan=1 colspan=1>-4</td><td rowspan=1 colspan=1>132</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>91.7</td></tr><tr><td rowspan=1 colspan=1>-3</td><td rowspan=1 colspan=1>132</td><td rowspan=1 colspan=1>124</td><td rowspan=1 colspan=1>93.9</td></tr><tr><td rowspan=1 colspan=1>-2</td><td rowspan=1 colspan=1>132</td><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>98.5</td></tr><tr><td rowspan=1 colspan=1>-1</td><td rowspan=1 colspan=1>132</td><td rowspan=1 colspan=1>131</td><td rowspan=1 colspan=1>99.2</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>132</td><td rowspan=1 colspan=1>132</td><td rowspan=1 colspan=1>100</td></tr></table>

b. Lay User Study:

A lay user study was performed with a total of 120 lay users from the intended use population. The lay users were in two age groups: 18 to 45, and 46 and older women with diverse educational and professional backgrounds. The lay users tested their own urine sample, provided a sample for professional testing, and took a questionnaire regarding their experience with the candidate device. The data show that the agreement between lay user results and professional results was $100 \%$ .

Lay user versus Clinical status   

<table><tr><td rowspan=2 colspan=1>Lay user Result</td><td rowspan=1 colspan=3>Clinical status</td></tr><tr><td rowspan=1 colspan=1>Pregnant</td><td rowspan=1 colspan=1>NotPregnant</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>99</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>120</td></tr></table>

Lay user versus Professional user   

<table><tr><td rowspan=2 colspan=1>Lay user</td><td rowspan=1 colspan=3>Professional user</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>99</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>120</td></tr></table>

The questionnaire results indicated that lay users found the test easy to use, the results clear and easy to read, and the instructions for use easy to understand.

# c. Lay user spiked sample study

A total of 120 lay users tested negative and positive urine samples. Samples were blinded and the order of testing was randomized. Professionals also conducted testing with the spiked urine samples. A comparison of lay user and professional results for the samples demonstrated $5 9 9 \%$ agreement.

d. Specificity study to determine false-positive result rate:

The incidence of positive test results from One Step Pregnancy Test among nonpregnant women was determined in three age groups: 18–40 years of age (premenopausal), 41–55 years of age (peri-menopausal) and ${ > } 5 6$ year of age (postmenopausal). A total of 433 subjects provided urine samples including 133 from premenopausal patients (also included in the method comparison study), 150 from perimenopausal patients, and 150 from post-menopausal patients. All 433 urine samples were tested with three lots of One Step Pregnancy Test devices. No positive results were observed in any of the age groups.

# D. Clinical Cut-Off:

Not applicable.

E. Expected Values/Reference Range: Not applicable.

# VIII Proposed Labeling:

The proposed labeling support substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.